Prescription brain neuromodulation therapies for clinical use at scale

Neurolief is a medical device company pioneering a new generation of physician-directed neuromodulation therapies for neuropsychiatric and neurological disorders.
The company has developed a non-invasive, multi-channel brain neuromodulation platform designed for both in-home and in-clinic use, enabling precise, focal stimulation of key neural pathways involved in mood and pain regulation.

Our flagship therapy, Proliv™Rx, is the first and only FDA-approved prescription neuromodulation therapy for Major Depressive Disorder (MDD) that can be delivered outside traditional clinical settings for patients who have not achieved adequate response to antidepressants. It is designed to integrate seamlessly into existing clinical workflows, providing physicians with a scalable, next-step therapy focused on advancing depression care

Neurolief is also the developer of Relivion®MG, an FDA-cleared and CE-marked neuromodulation system for the treatment of migraine, extending the platform’s clinical impact across neurological indications.

Neurolief’s team brings deep expertise in neuromodulation, clinical psychiatry and neurology, biomedical engineering, and regulatory strategy. With extensive experience in developing advanced medical technologies, the team translates brain stimulation science into safe, clinically validated, physician-driven therapies addressing some of the largest unmet medical needs worldwide.